UROCOR INKS PACT TO MATCH DIAGNOSTICS WITH THERAPEUTICS
HERE’S A PIONEERING EFFORT to more closely link diagnostics and therapeutics into a single product package.
UroCor, Inc. and Mallinckrodt, Inc. signed an agreement that allows Mallinckrodt to sell and distribute UroCor’s new radiation treatment for prostate cancer.
UroCor’s product, ProstaSeed I-125, is a radioactive pellet used in brachytherapy. This
Subscriber-Only Content. Please Log In.
You are trying to access subscribers-only content. If you are a subscriber, please log in.
If you are not a subscriber, click here to see subscription offers.
Subscribers will have instant access to the Dark Report library, 1997-the present, giving you the most convenient, accessible archive available in laboratory business intelligence today!
To read our FREE article previews, go to The Dark Report Insider.